
Revolutionizing R-R cHL Treatment: Affimed’s Acimtamig and AlloNK Combination Proves Safe and Effective for Relapsed/Refractory Classical Hodgkin Lymphoma Patients
Revolutionizing R-R cHL Treatment: Affimed’s Acimtamig and AlloNK Combination Proves Safe and Effective for Relapsed/Refractory Classical Hodgkin Lymphoma Patients MANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) Affimed, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a…